David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
Novant Health announced that it will soon be the first healthcare provider in the Carolinas to offer an incision-free brain “surgery” technique to treat essential tremor and tremors caused by Parkinson’s ... Read more
The small molecule anle138b has shown “excellent” safety and tolerability profiles in a first study in healthy volunteers, and reached therapeutic dose levels in the blood, according to its ... Read more
Denali Therapeutics announced a partnership with Biogen to jointly develop and advance DNL151, an investigational small molecule treatment for Parkinson’s disease, to late-stage clinical testing following results from ongoing Phase 1/1b trials. The ... Read more
The nonprofit Parkinson’s UK announced an additional £1 million (about $1.3 million) award to NRG Therapeutics, advancing its work into potential treatments that can rescue damaged mitochrondria — the cellular ... Read more
Axial Biotherapeutics announced a $440,000 grant from the Michael J. Fox Foundation for Parkinson’s Research to support its efforts to develop a model that can mimic the nervous system of the ... Read more
The U.S. Food and Drug Administration (FDA) has approved a new app developed by Abbott, called the Patient Controller app, which will allow patients with chronic neurological conditions to ... Read more
Seelos Therapeutics has begun a preclinical study in rodents to test a gene therapy approach to deliver its investigational candidate SLS-007, a potential treatment for Parkinson’s disease. Results are ... Read more